Market Overview

Youku Tudou Signs Licensing Deal with Paramount Pictures to Expand Offerings on Subscription Service

Share:

Youku Tudou, Inc. (NYSE: YOKU), a leading multi-screen entertainment and media company in China ("Youku Tudou" or the "Company"), announced today that it has entered into a content licensing agreement with Paramount Pictures that will bring more than a hundred top titles from Paramount Picture's film library to Youku Tudou. Popular franchises and titles such as Transformers, Shrek, Star Trek, Mission: Impossible and Forrest Gump will be viewable through Youku Tudou's subscription service and select future Paramount releases will be available through TVOD.

Youku Tudou's subscription service currently offers a wide selection of content from both foreign and domestic studios. More licensed content as well as Youku Tudou web-native content will be added on an ongoing basis, continually enriching the value proposition of the Company's subscription services.

"The consumer-driven demand for premium online services in China is growing rapidly. With top branded content such as Paramount Picture's array of films, our commitment to enhancing our subscription services to create a premium experience and drive consumer-based revenue continues in earnest," said Victor Koo, Chairman and CEO of Youku Tudou.

With this agreement, Youku Tudou will boast a library of over 4,000 movie titles that encompass domestic, foreign and original productions.

Posted-In: News Press Releases

 

Related Articles (YOKU)

View Comments and Join the Discussion!
Fastest Market News Application
You'll Hear It First On Pro
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

XenoPort Announces Positive Phase 2 Study Results for XP23829 as a Potential Treatment for Patients with Psoriasis

Must Watch Stocks for Today